View clinical trials related to Plaque Psoriasis.
Filter by:Purpose: To develop a real time national clinical database to support and share best practices, 1. To generate hypotheses for future clinical research 2. To understand how AMEVIVE is used in routine clinical practice/real world setting. Each patient visit will include the following observational endpoints: 1. AMEVIVE dosing 2. Number of courses 3. Concomitant treatment 4. Response to treatment (patient and physician global assessments) 5. Status of other psoriasis-related medical conditions 6. Time to re-treatment.
An open label, single arm study to evaluate the study and efficacy of efalizumab in combination with NB-UVB. Weeks 1-12 efalizumab will be administered once a week in combination with NB-UVB three times per week. Weeks 13-24 efalizumab monotherapy will continue. Weeks 25-36 subjects will be followed for safety. Subjects with moderate to severe plaque psoriasis often require more than one therapy to treat their disease. Because of the different mechanisms of action, it is thought that combined efalizumab and NB-UVB may be more effective and have a more rapid onset than either treatment alone.
The purpose of this study is to investigate the incidences of adverse events for patients with plaque psoriasis treated with Enbrel under usual care settings.
The main objectives of the project are: - To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI) - To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.
This is a clinical study in two phases. The first phase compares the effect of an ointment containing parathyroid hormone (PTH) with the effect of a placebo ointment (inactive ointment without PTH) on psoriasis lesions. Neither the study participants nor the researchers will know who is receiving PTH ointment and who is receiving placebo until the end of this first study phase. The second phase is a study of the PTH ointment on large areas of psoriasis to find out how long the effects last.